SYRE — Spyre Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636282 ·
Last close
$93.81
Market Cap
$8.91B
52W High
$110.64
52W Low
$23.01
ADV30
1,146,491
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -105,719,000 | -96,121,000 | 1,099,728,000 | 82,727,000 | 48,193,000 |
| Jun 2026 | 0 | — | -81,639,000 | -36,200,000 | 1,173,003,000 | 162,007,000 | 71,862,000 |
| Mar 2026 | 0 | — | -75,641,000 | -69,005,000 | 763,953,000 | 97,185,000 | 93,142,000 |
| Dec 2025 | 0 | — | -57,172,000 | -62,530,000 | 777,781,000 | 85,721,000 | 62,545,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-249,322,000
Investing CF
$-492,536,000
Financing CF
$759,688,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.81
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,328,961,000
Inventory
—
Receivables
—
ST Investments
$989,180,000
EBIT TTM
$-320,171,000
Pretax Income TTM
$-263,856,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -219,562,000 | — | 777,781,000 | 62,545,000 | 715,236,000 | -169,252,000 |
| Dec 2024 | 0 | -208,566,000 | -208,018,000 | 608,484,000 | 90,680,000 | 517,804,000 | -157,410,000 |
| Dec 2023 | 886,000 | -128,564,000 | -338,790,000 | 341,859,000 | 157,843,000 | 184,016,000 | -99,910,000 |
| Dec 2022 | 2,329,000 | -84,781,000 | -83,815,000 | 71,144,000 | 20,839,000 | 50,305,000 | -80,144,000 |
| Dec 2021 | — | — | -65,801,000 | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-178,918,000
OpCashFlow TTM
—
Assets (Latest)
$1,173,003,000
Forward EPS
$-3.64
Max Pain — expiry 2027-01-15
max pain strike: $100.00 · spot: $101.46 · call oi: 174 · put oi: 1,034
Expected Move to 2027-01-15:
±$34.90
(34.40%) —
implied range
$66.56 –
$136.36
· ATM straddle on $100.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $8.53B | $10.67 | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.53B | $305.06 | — |
| TGTX | TG THERAPEUTICS, INC. | $9.48B | $62.71 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $9.80B | $421.99 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
News headlines (Yahoo Finance, 1h cache)
Spyre Therapeutics to Participate in Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
Spyre Therapeutics (SYRE) Stock Trades At A Premium To Book Value
2026-11-07 21:10 · Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
2026-11-06 21:05 · Yahoo
Spyre Therapeutics: Q3 Earnings Snapshot
2026-11-03 21:12 · Yahoo
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-03 21:01 · Yahoo
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
2026-10-24 01:15 · Yahoo
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
2026-10-20 16:48 · Yahoo
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
2026-10-18 13:30 · Yahoo
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
2026-10-08 17:15 · Yahoo
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
2026-10-06 17:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.